Major Licensing Deals and M&A
Executive Summary - June 2 to June 9, 2026
The June 2-9 window was M&A-led and US-centric. Two bolt-on acquisitions announced June 8, 2026 totaled up to roughly $3.0B, with about $2.25B in guaranteed or near-term cash. Incyte agreed to acquire Vega Therapeutics for up to $2.0B to add a Phase 3 bleeding-disorder antibody, and Johnson & Johnson agreed to buy Firefly Bio for $1.0B in cash for its pan-KRAS degrader antibody conjugate platform.
The large China-to-West licensing engine paused in-window: no major cross-border out-licensing deal was announced between June 2 and June 9. The prior fortnight's pacts - Pfizer-Innovent (up to $10.5B), Lilly-Haisco and Lilly-Hanmi - continue to move toward their Q3 2026 closes. As always, BD professionals should anchor to near-term cash rather than headline biobucks; this week's late-stage US deals carried far higher upfront-to-total ratios than early-stage China-out portfolio licensing.
M&A Transactions - June 2 to June 9, 2026
| Date | Acquirer | Target | Deal Value | Strategic Rationale |
|---|---|---|---|---|
| Jun 8, 2026 (announced) | Incyte | Vega Therapeutics (US; wholly owned subsidiary of Star Therapeutics) | $1.25B upfront; up to $750M sales milestones; up to $2.0B total | Equity acquisition adding VGA039, a first-in-class investigational monoclonal antibody targeting Protein S to restore hemostasis, in Phase 3 (VIVID-6) for von Willebrand disease (VWD), the most common inherited bleeding disorder. VGA039 holds FDA Breakthrough Therapy, Fast Track, orphan drug and rare-pediatric designations and offers once-monthly subcutaneous dosing versus the 2-3 weekly IV factor infusions used today. Expected to close Q3 2026, subject to Hart-Scott-Rodino review. Expands Incyte's hematology franchise into bleeding disorders. |
| Jun 8, 2026 (announced) | Johnson & Johnson | Firefly Bio (US) | $1.0B cash | Acquires Firefly's proprietary Firelink degrader antibody conjugate (DAC) platform, which delivers a selective protein degrader into tumor cells while sparing healthy tissue, targeting pan-KRAS and other drivers of hard-to-treat solid tumors. Preclinical-stage; expected to close later in 2026, subject to regulatory clearance. Extends J&J's antibody-engineering and oncology pipeline into KRAS-driven cancers. |
No major licensing or partnering transaction, including China-out, was announced in the June 2-9 window. Section 1 this week therefore centers on M&A.
Weekly Takeaways
- M&A over licensing this week: two US bolt-ons (Incyte-Vega, J&J-Firefly) worth up to roughly $3.0B dominated, while no cross-border out-licensing deal landed in the window.
- KRAS keeps pulling capital. J&J's Firefly buy (a pan-KRAS degrader ADC platform) lands days after ASCO's daraxonrasib pancreatic-cancer readout (covered last issue). China-origin KRAS and pan-RAS programs should expect continued buyer interest - see the standing KRAS G12V mandate in Section 4.
- Degrader antibody conjugates (DACs) emerge as the next ADC frontier, extending the ADC wave from cytotoxic payloads to targeted protein degraders, where differentiated linker and payload IP commands premiums.
- Hematology bolt-ons are priced on near-term cash. Incyte's $1.25B upfront for a single Phase 3 asset implies an upfront-to-total ratio near 63% - far above the roughly 6% seen in early-stage China-out portfolio licensing - reflecting late-stage de-risking.
- What to watch next week: EHA 2026 (June 11-14, Stockholm) brings late-stage hematology readouts (Agios mitapivat RISE UP in sickle cell; J&J's 30-plus abstracts), plus HSR and closing progress on Pfizer-Innovent and Lilly-Haisco.
Global Biomedicine Highlights
Clinical Readouts & Regulatory - June 2 to June 9, 2026
June 8, 2026 - Gilead and Merck Report Positive Phase 3 Topline for Once-Weekly Oral Islatravir/Lenacapavir in HIV (ISLEND-1, ISLEND-2)
Gilead and Merck announced that the investigational once-weekly single-tablet regimen of islatravir 2mg/lenacapavir 300mg (ISL/LEN) met its primary efficacy endpoint at Week 48 in both Phase 3 ISLEND trials. The primary endpoint was the proportion of participants with HIV-1 RNA at or above 50 copies/mL at Week 48 by the FDA snapshot algorithm. In the double-blind ISLEND-1 trial (switch from Biktarvy), ISL/LEN was statistically non-inferior to Biktarvy; in the open-label ISLEND-2 trial (switch from standard-of-care daily antiretroviral therapy), ISL/LEN was statistically non-inferior to standard of care. The safety profile was generally comparable to comparators with no new safety concerns, and the companies plan to file the data with regulators globally.
BD Implication: If approved, this would be the first long-acting oral once-weekly HIV treatment, reinforcing dosing frequency as the competitive axis in HIV and validating long-acting oral platforms as a partnering theme - relevant to China-origin long-acting and formulation technologies seeking Western development partners.
Regulatory and calendar note: in-window clinical news was light, with the window falling between ASCO (closed June 2 and covered last issue) and EHA 2026 (opens June 11). The marquee in-window readout was ISLEND; other readouts reviewed this week dated outside the June 2-9 window and were omitted from this issue accordingly.
Job Postings
Executive and senior-level openings across C-suite, BD&L, R&D leadership, manufacturing, and medical affairs - spanning both U.S. and China-based employers - are tracked on the dedicated Job Board. BD&L talent searches frequently pair with the buyer and fund mandates on the Opportunity Board below.
View the Job BoardBD&L Opportunity Board
Active In-Licensing Mandates (Standing - Carried Forward)
Several new buyer in-licensing mandates were registered this week - spanning rare and special movement disorders, motor neuron disease and rare epilepsy; TRAIL agonists; oligonucleotide and small-nucleic-acid programs; and cardiovascular and kidney disease - and are listed first below. The standing mandates from prior weeks continue beneath them. All are US/EU buyer or fund mandates with ex-China or global rights preferred unless noted, and new assets matching any mandate can be routed via the BD inbox at any time.
Rare & Special Movement Disorders, Motor Neuron Disease, Rare Epilepsy
US/EU companies are in-licensing novel, potentially disease-modifying therapies for rare and special movement disorders, motor neuron disease, and rare epilepsy. Projects at any stage are welcome and modality is open. Ex-China / global rights preferred.
TRAIL Agonist - Target Interest
US/EU companies are in-licensing TRAIL-agonist programs. Assets from preclinical candidate (PCC) stage through Phase II can be considered; indication flexible. Ex-China / global rights preferred.
Oligonucleotide & Small Nucleic Acid Programs (Fund Mandate)
A well-established US/EU fund is seeking siRNA, antisense oligonucleotide, and small nucleic acid programs. No restriction on disease area; preclinical assets are acceptable. Ex-China / global rights preferred.
Cardiovascular & Kidney Disease - Multi-Modality
US/EU companies are in-licensing cardiovascular and kidney disease programs across modalities - small molecules, large molecules, siRNA, peptides, and antisense oligonucleotides. Preclinical assets are acceptable. Ex-China / global rights preferred.
KRAS G12V - Target-Specific (Oncology)
US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.
AL Amyloidosis - Disease-Area Mandate
US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.
ANCA-Associated Vasculitis (GPA, MPA, EGPA)
US/EU buyer disease-area mandate for ANCA-associated vasculitis across GPA, MPA, and EGPA. Small molecule or biologic; PCC stage or later. Mechanism open.
Anemia of Chronic Kidney Disease
US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.
Anemia of Inflammatory Bowel Disease
US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.
CCR3 Antagonist - Target Interest
US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAG1 Agonist - Target Interest
US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.
ENTPD1 / CD39 Antagonist - Target Interest
US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.
Geographic-Arbitrage: Chinese Phase I/IIa Assets
Fund invests in Chinese-originated Phase I or IIa assets, re-runs / extends clinical development in EU/US (Western data is more readily accepted by MNCs), then out-licenses or sells to MNCs.
Newco Formation around Phase III Programs
Large European/American funds building purpose-built Newcos around Phase III clinical-stage programs in Oncology, Autoimmune, and CNS. Asset contributable or out-licensable into a fund-backed Newco structure.
Sourcing Cross-Reference - What to Flag into Biolink
For readers with assets or intros that match the mandates above, the following cross-reference summarizes what Biolink can route directly to the relevant buyer or fund.
| Buyer Mandate | What to Source / Flag to Biolink |
|---|---|
| Rare/Special Movement Disorders, MND, Rare Epilepsy | Disease-modifying programs for rare/special movement disorders, motor neuron disease, or rare epilepsy; any stage; modality open. |
| TRAIL Agonist | TRAIL-agonist programs from PCC through Phase II; indication flexible. |
| siRNA / ASO / Small Nucleic Acid (fund) | Oligonucleotide and small-nucleic-acid programs - siRNA, antisense, small nucleic acids; any disease area; preclinical acceptable. |
| Cardiovascular & Kidney Disease | CV and renal programs - small molecule, large molecule, siRNA, peptide, or antisense; preclinical acceptable. |
| KRAS G12V (Oncology) | KRAS G12V-targeted programs, small molecule or biologic, IND-cleared or later; ex-China / global rights. |
| AL Amyloidosis | Programs for AL amyloidosis at PCC stage or later; small molecule or biologic; mechanism open. |
| ANCA-Associated Vasculitis | Programs addressing GPA, MPA, or EGPA at PCC stage or later; small molecule or biologic. |
| Anemia of CKD | Programs for anemia of chronic kidney disease at PCC stage or later; small molecule or biologic. |
| Anemia of IBD | Programs for anemia of inflammatory bowel disease at PCC stage or later; small molecule or biologic. |
| CCR3 Antagonist | CCR3 antagonist programs; preclinical acceptable; indication flexible. |
| JAG1 Agonist | JAG1 (Jagged-1) agonist programs; preclinical acceptable; indication flexible. |
| ENTPD1 / CD39 Antagonist | ENTPD1 (CD39) antagonist programs; preclinical acceptable; immuno-oncology focus. |
| Fund - China Phase I/IIa geographic-arbitrage | Chinese sponsor with a clean Phase I or IIa readout, open to a Western development plan; fund leads EU/US clinical work and downstream MNC out-license. |
| Fund - Newco around Phase III asset | Late-stage (Ph III) programs in Oncology, Autoimmune, or CNS where the originator is open to a fund-backed Newco. |
Featured License-Out
A China-based biotech is seeking global partners for a first-in-class (FIC) immunotherapy platform targeting autoimmune diseases. The platform is built on a proprietary antigen-specific tolerance technology designed to modulate immune response without systemic immunosuppression - a mechanism that, if validated, would directly address the central limitation of currently marketed biologics in this space.
| Attribute | Detail |
|---|---|
| Opportunity Type | License-Out - global partnership sought |
| Originator | China-based biotech (fully integrated; R&D, clinical, manufacturing, global supply chain) |
| Platform | First-in-class (FIC) immunotherapy platform based on proprietary antigen-specific tolerance technology. Designed to modulate the immune response without systemic immunosuppression. |
| Lead Asset - Stage | Phase II in Graves' disease (GD) |
| Additional Indications | Thyroid eye disease (TED) - Multiple sclerosis (MS) - Type 1 diabetes (T1D) |
| Clinical Readouts to Date | Safety: no severe AEs in Phase I. Efficacy: meaningful reduction in disease biomarkers. Mechanism benefit: potential for long-term disease remission via immune-tolerance induction. |
| IP Position | >150 granted patents; multiple FIC assets in the pipeline |
| Deal Type Sought | Global partnership / out-license discussions (ex-China rights negotiable) |
| Contact | BD@biorichinc.com (direct message also welcome) |
The lead asset is Phase II and the platform produces multiple FIC programs in autoimmune disease - squarely within the autoimmune mandate from Western buyers. For the geographic-arbitrage fund model, the Phase II GD program could also serve as a candidate for a Western Phase II/III re-read with fund capital, particularly given the clean Phase I safety profile.
Contact & Submissions
- To submit assets matching any mandate above: BD@biorichinc.com (include modality, stage, last clinical readout, and territory availability).
- Browse the full, filterable opportunity set - including out-licensing assets - on the Licensing Opportunities page.
- Role cross-reference - see Section 3 (Job Postings) for BD&L professionals available for hire (VP BD, licensing counsel).
BioLink Weekly - Section 4, BD&L Opportunity Board. Prepared June 9, 2026. Buyer and fund mandates are summarized from direct briefings; specific terms available upon NDA. Deal terms and clinical figures elsewhere in this issue are drawn from company press releases and named reputable sources; unverifiable items were omitted.
BioLink Weekly is published by BioRich International, Princeton NJ.
lisa.fan@biorichinc.com